TY - JOUR
T1 - Lance Armstrong' s era of performance – Part II
T2 - Revisiting his time trial wins
AU - Lodewijkx, Hein F.M.
AU - Bos, AER
N1 - exported from refbase (http://publicaties.ou.nl/show.php?record=1299), last updated on Tue, 31 Jan 2017 11:21:06 +0100
PY - 2014
Y1 - 2014
N2 - This archival study (N = 100) compared Lance Armstrong’s time trial wins to victories demonstrated by all former multiple Grand Tour winners (1949–1995; Coppi, Anquetil, Merckx, Hinault, Indurain) and by riders who won similar races in the three major European Grand Tours (Tour de France, Giro d’Italia, and Vuelta a España) from 2006 to 2013, who were either involved in doping affairs or not. Regression analyses yielded a non–significant M = 142 seconds difference between Armstrong vs. the aggregated other riders (ΔR2 = .001, p = .20). The effect emerged after controlling for the influence of competition year (b = -12.23 s per year, ΔR2 = .045, p ≤ .001) and trial distances (b = 84.64 s per kilometer trial distance, ΔR2 = .933, p ≤ .001) on the variation in riders’ speed. Furthermore, Armstrong along with other riders who were suspended for doping use or who acknowledged having used doping in the 2006–2013 periods did not outperform riders who were not involved in doping affairs during the same years (M = -68 s, ΔR2 = .01, p = .35). Findings disprove the argument from ignorance, a false logic which refers to the often heard opinion that cyclists’ performances over time (including Armstrong’s wins) are mainly determined by their use of increasingly potent doping aids. However, in contrast to this logic, the distances of the time trials constitute the main determinant of riders’ performances rather than the year in which they competed, and riders engaged in doping affairs did not significantly outperform riders who were not.
AB - This archival study (N = 100) compared Lance Armstrong’s time trial wins to victories demonstrated by all former multiple Grand Tour winners (1949–1995; Coppi, Anquetil, Merckx, Hinault, Indurain) and by riders who won similar races in the three major European Grand Tours (Tour de France, Giro d’Italia, and Vuelta a España) from 2006 to 2013, who were either involved in doping affairs or not. Regression analyses yielded a non–significant M = 142 seconds difference between Armstrong vs. the aggregated other riders (ΔR2 = .001, p = .20). The effect emerged after controlling for the influence of competition year (b = -12.23 s per year, ΔR2 = .045, p ≤ .001) and trial distances (b = 84.64 s per kilometer trial distance, ΔR2 = .933, p ≤ .001) on the variation in riders’ speed. Furthermore, Armstrong along with other riders who were suspended for doping use or who acknowledged having used doping in the 2006–2013 periods did not outperform riders who were not involved in doping affairs during the same years (M = -68 s, ΔR2 = .01, p = .35). Findings disprove the argument from ignorance, a false logic which refers to the often heard opinion that cyclists’ performances over time (including Armstrong’s wins) are mainly determined by their use of increasingly potent doping aids. However, in contrast to this logic, the distances of the time trials constitute the main determinant of riders’ performances rather than the year in which they competed, and riders engaged in doping affairs did not significantly outperform riders who were not.
KW - doping
KW - professional cycling
KW - time trial performance
UR - http://pubs.sciepub.com/ajssm/2/5/4/index.html
U2 - 10.12691/ajssm-2-5-4
DO - 10.12691/ajssm-2-5-4
M3 - Article
SN - 2333-4606
VL - 2
SP - 194
EP - 201
JO - American Journal of Sports Science and Medicine
JF - American Journal of Sports Science and Medicine
IS - 5
ER -